Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Raises Target Price to $7
A Quick Look at Today's Ratings for Nevro(NVRO.US), With a Forecast Between $7 to $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Truist Adjusts Price Target on Nevro to $7 From $5.50, Maintains Hold Rating
A Quick Look at Today's Ratings for Nevro(NVRO.US), With a Forecast Between $6 to $9
Nevro Price Target Cut to $6.00/Share From $7.00 by Piper Sandler
Nevro Is Maintained at Underweight by Piper Sandler
Nevro Analyst Ratings
Nevro Corp (NVRO) Receives a Sell From Piper Sandler
Hold Rating on Nevro Corp Amid Cost-Cutting Concerns and Upcoming Product Launches
JMP Securities Sticks to Its Hold Rating for Nevro Corp (NVRO)
Mizuho Securities Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $8
RBC Capital Maintains Nevro(NVRO.US) With Hold Rating, Maintains Target Price $7
Nevro Is Maintained at Neutral by Citigroup
Nevro Analyst Ratings
Citi Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $6
Nevro Corp: Underperform Rating With Reduced Price Objective Amid Revenue Decline and Market Challenges
RBC Capital Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $7
RBC Capital Keeps Their Hold Rating on Nevro Corp (NVRO)
J.P. Morgan Maintains Nevro(NVRO.US) With Sell Rating